Pharming Group NV (NYSEEuronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) announced that new data froman open-label extension of the pivotal Phase III clinical study with RUCONEST(®)(recombinant human C1 esterase inhibitor, or rhC1INH) will be featured in aposter presentation on November 9 & 10, 2013 at the 2013 American College ofAllergy, Asthma & Immunology Annual Scientific Meeting at the Convention Centerin Baltimore, Maryland. The poster is titled, Efficacy and Safety ofRecombinant Human C1 Esterase Inhibitor for Acute Attacks of HereditaryAngioedema: An Open-Label Study.
Help employers find you! Check out all the jobs and post your resume.
